A study of gilteritinib in adults with advanced ALK-positive non-small cell lung cancer (NSCLC)
2215-CL-5201
Phase 1 other active
Quick answer
A study of gilteritinib in adults with advanced ALK-positive non-small cell lung cancer (NSCLC) for Locally advanced or metastatic NSCLC is a Phase 1 program (other) at Astellas Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Astellas Pharma GmbH
- Indication
- Locally advanced or metastatic NSCLC
- Phase
- Phase 1
- Modality
- other
- Status
- active